Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tetramethylpyrazine is the active ingredient of a Chinese herbal medicine. In this study, tetramethylpyrazine was tested for its activities in irradiated bone marrow stromal QXMSC1 cells. The proliferation of QXMSC1 cells was measured by MTS assay kit and flow cytometry. To identify proteins involved in the processes of cellular and molecular response of tetramethylpyrazine to irradiation damage, we comparatively analyzed the proteome of nonirradiated, irradiated and tetramethylpyrazine treated QXMSC1 cells. Reverse transcriptase polymerase chain reaction (RT-PCR) were used to validate the differentially expressed proteins. 20 Gy 60Co gamma irradition inhibited QMSC1 cells growth and tetramethylpyrazine could reverse of this action due to stimulating QXMSC1 cells from G1 to S progression. Proteomic analytical results showed that 18 spots were changed in irradiated QXMSC1 cells, and 15 spots matched with known proteins after database searching. The expression level of proteins such as
translationally controlled tumor protein
(
TCTP
), and
galectin-3
, were increased in irradiated QXMSC1 cells, while calmodulin, pyruvate kinase were decreased. Tetramethylpyrazine could prevent this change or reverse to some degree. The function of these proteins involves in hematopoiesis, cell cycle and signal transduction. The changes of these proteins were confirmed by RT-PCR at mRNA levels. This study suggested that stimulating proliferation via tetramethylpyrazine played an important role in the cure effect on irradiated QXMSC1 cells and was helpful to deeply understand the mechanism of tetramethylpyrazine at the molecular level.
...
PMID:Proteomic analysis of the effects of tetramethylpyrazine on irradiated QXMSC1 cells. 1726 90
The prostate-specific antigen (PSA) test has served as a blood marker of prostate cancer (PCa), and for monitoring recurrence/metastasis in patients after therapeutic intervention. However, the applicability/reliability of the PSA test was recently questioned as it is not without challenges, in particular in men who have PCa without an elevated PSA (false negative), or in men who are disease-free with elevated levels of PSA (false positive).
Galectin-3
is a
tumor-associated protein
; present in the seminal fluid and is a substrate for the PSA enzyme e.g., a chymotrypsin-like serine protease. We hypothesized that the cleavage status and level of
galectin-3
in the prostate tissue and sera are associated with PCa. Thus, we compared
galectin-3
levels obtained from sera of non-cancer urology patients to those of metastatic PCa patients. The data were confirmed by analyzing PCa tissue arrays. Here, we report that
galectin-3
levels in the sera of patients with metastatic PCa were uniformly higher as compared to the non-cancer patient controls. The data suggest that
galectin-3
serum level may be a useful serum complementary marker to the PSA blood test to be used for initial and follow-up PSA complimentary diagnostic/prognostic tool for recurrence in PCa patients.
...
PMID:Galectin-3: a possible complementary marker to the PSA blood test. 2362 38